Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0000950170-25-036341
Filing Date
2025-03-10
Accepted
2025-03-10 16:25:20
Documents
9

Document Format Files

Seq Description Document Type Size
1 424B3 424b3_okur_10-k_2024_202.htm 424B3 3906677
2 GRAPHIC img206454441_0.jpg GRAPHIC 8875
3 GRAPHIC img206454441_1.jpg GRAPHIC 458499
4 GRAPHIC img206454441_2.jpg GRAPHIC 611593
5 GRAPHIC img206454441_3.jpg GRAPHIC 118029
6 GRAPHIC img206454441_4.jpg GRAPHIC 107874
7 GRAPHIC img206454441_5.jpg GRAPHIC 75231
8 GRAPHIC img206454441_6.jpg GRAPHIC 649137
9 GRAPHIC img206454441_7.jpg GRAPHIC 1035305
  Complete submission text file 0000950170-25-036341.txt   8128236
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-282792 | Film No.: 25724071
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)